Compare STBA & KARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | STBA | KARD |
|---|---|---|
| Founded | 1902 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 1995 | 2026 |
| Metric | STBA | KARD |
|---|---|---|
| Price | $50.46 | $20.91 |
| Analyst Decision | Hold | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $43.00 | N/A |
| AVG Volume (30 Days) | ★ 235.8K | 185.2K |
| Earning Date | 04-23-2026 | N/A |
| Dividend Yield | ★ 3.29% | N/A |
| EPS Growth | ★ 2.35 | N/A |
| EPS | ★ 1.96 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.20 | N/A |
| Revenue Next Year | $4.14 | N/A |
| P/E Ratio | $25.61 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $34.38 | $19.58 |
| 52 Week High | $53.50 | $27.00 |
| Indicator | STBA | KARD |
|---|---|---|
| Relative Strength Index (RSI) | 46.99 | 47.67 |
| Support Level | $48.99 | $19.67 |
| Resistance Level | $53.50 | $24.82 |
| Average True Range (ATR) | 0.72 | 1.40 |
| MACD | -0.31 | 0.07 |
| Stochastic Oscillator | 23.03 | 33.95 |
S&T Bancorp Inc is a financial holding company providing a full range of financial services to individuals and businesses in Pennsylvania and Ohio, including retail and commercial banking products, cash management, and trust and brokerage services. Through its subsidiary, it offers consumer, commercial, and small business banking services, including time and demand deposits, commercial and consumer loans, brokerage and trust services, and manages private investment accounts for individuals and institutions. The company earns revenue mainly from interest on loans and securities and fees for financial services, with net interest income as the principal source of revenue, and incurs expenses for deposits, funding sources, provision for credit losses, and operating costs.
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.